CorMedix (NASDAQ:CRMD) & Helix BioPharma (OTCMKTS:HBPCF) Head-To-Head Comparison

Helix BioPharma (OTCMKTS:HBPCF) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Volatility and Risk

Helix BioPharma has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Earnings and Valuation

This table compares Helix BioPharma and CorMedix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helix BioPharma	N/A	N/A	-$6.82 million	($0.10)	-4.55
CorMedix	$60,000.00	10,598.77	-$46.34 million	($0.81)	-12.94

Helix BioPharma has higher earnings, but lower revenue than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

34.2% of CorMedix shares are owned by institutional investors. 7.6% of Helix BioPharma shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Helix BioPharma and CorMedix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helix BioPharma	N/A	N/A	-1,097.76%
CorMedix	N/A	-79.21%	-64.68%

Analyst Recommendations

This is a breakdown of recent recommendations for Helix BioPharma and CorMedix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helix BioPharma	0	0	0	0	0.00
CorMedix	0	0	6	0	3.00

CorMedix has a consensus price target of $15.67, suggesting a potential upside of 49.49%. Given CorMedix’s stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Helix BioPharma.

Summary

CorMedix beats Helix BioPharma on 7 of the 12 factors compared between the two stocks.

About Helix BioPharma

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.